Pharma companies devote a lot of resources to winning over the U.K.'s drug price watchdog, the National Institute for Health and Care Excellence (NICE). They compile data to prove the benefits of new products justify their high prices, they prepare detailed rebuttals when NICE says a drug is too expensive, and the like. Now, NICE says it will start looking beyond pharma companies for data, to get a more complete picture of whether new drugs are really worth their high costs. Report